[Participation in the global study. Activities and issues from the bedside]

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Context:

• Global collaboration in anti-cancer drug development is increasing, involving Japan, the US, and Europe.
• Significant challenges exist in translating preclinical findings to bedside applications.
• Robust infrastructure is crucial for effective clinical research and drug deployment.

Purpose:

• To highlight the growing trend of global studies in anti-cancer drug development.
• To identify key challenges in clinical translation and infrastructure development.
• To emphasize the importance of quality and speed in early-phase (Phase I) clinical trials.

Summary:

• Anti-cancer drug development is increasingly globalized, with major contributions from Japan, the US, and Europe.
• Addressing bedside issues and establishing necessary infrastructure are critical unmet needs.
• Maintaining high quality and rapid progression in Phase I studies is a key focus.

Impact:

• Facilitates international cooperation in oncology research.
• Informs strategies for overcoming clinical translation barriers.
• Accelerates the development pipeline for new anti-cancer medications.